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ABSTRACT
KUJALA, U. M., T. PALVIAINEN, P. PESONEN, K. WALLER, E. SILLANPÄÄ, M. NIEMELÄ, M. KANGAS, H. VÄHÄ-YPYÄ, H.
SIEVÄNEN, R. KORPELAINEN, T. JÄMSÄ, M. MÄNNIKKÖ, and J. KAPRIO. Polygenic Risk Scores and Physical Activity.Med. Sci.
Sports Exerc., Vol. 52, No. 7, pp. 1518–1524, 2020. Purpose: Polygenic risk scores (PRS) summarize genome-wide genotype data into
a single variable that produces an individual-level risk score for genetic liability. PRS has been used for prediction of chronic diseases
and some risk factors. As PRS has been studied less for physical activity (PA), we constructed PRS for PA and studied howmuch variation
in PA can be explained by this PRS in independent population samples. Methods: We calculated PRS for self-reported and objectively
measured PA using UK Biobank genome-wide association study summary statistics, and analyzed how much of the variation in self-
reported (MET-hours per day) and measured (steps and moderate-to-vigorous PA minutes per day) PA could be accounted for by the
PRS in the Finnish Twin Cohorts (FTC; N = 759–11,528) and the Northern Finland Birth Cohort 1966 (NFBC1966; N = 3263–4061).
Objective measurement of PA was done with wrist-worn accelerometer in UK Biobank and NFBC1966 studies, and with hip-worn accel-
erometer in the FTC.Results: The PRS accounted from 0.07% to 1.44% of the variation (R2) in the self-reported and objectively measured
PA volumes (P value range = 0.023 to <0.0001) in the FTC and NFBC1966. For both self-reported and objectively measured PA, indi-
viduals in the highest PRS deciles had significantly (11%–28%) higher PA volumes compared with the lowest PRS deciles (P value
range = 0.017 to <0.0001). Conclusions: PA is a multifactorial phenotype, and the PRS constructed based on UK Biobank results
accounted for statistically significant but overall small proportion of the variation in PA in the Finnish cohorts. Using identical methods
to assess PA and including less common and rare variants in the construction of PRS may increase the proportion of PA explained by the
PRS. Key Words: GENE, EXERCISE, HERITABILITY, HIDDEN HERITABILITY
Based on family and twin studies, genetic factors under-lie an individual’s propensity to participate in physicalactivity (PA) (1–4). Genome-wide association studies
(GWAS) have found a few loci that have genome-wide statis-
tically significant association with PA, but the effect sizes
found are small (5–7).
Polygenic risk score (PRS) or also called polygenic score is
a score based on variation in multiple genetic loci and their as-
sociated weights. It serves as the best prediction for the trait
that can be made when accounting for variation in multiple ge-
netic variants (8,9). Genome-wide association analyses com-
paring disease cases with controls have identified thousands
of genetic loci associated with complex disease risk, and geno-
mic information has become a potential candidate for improv-
ing disease risk assessment (10). Although PRS has been
calculated for many chronic diseases and applied for its predic-
tive value, there is limited amount of research for predicting
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PA levels using PRS for PA (5,6). In particular, we lack infor-
mation on how the constructed PRS for PA predict PA levels
in independent cohorts with differing ancestry and with differ-
ing methods to assess self-reported and objectively measured
PA levels. There has been much discussion on the genetic de-
terminants underlying physical inactivity, and it would be
helpful to identify those individuals for whom PA participa-
tion is difficult. In exercise interventions, these individuals
may need tailored exercise programs with more support and
supervision to gain the benefits of exercise therapy.
PA is a multifactorial behavior with many environmental
and genetic factors influencing the volume of overall PA.
Questionnaires and accelerometers are among the most used
methods in assessing PA levels, although different methods
have their strengths and challenges (11,12). Self-reported
leisure-time PA and measured overall PA levels may have
same but also different determinants. Age, sex, obesity (13),
and chronic diseases (14) are typical examples of other char-
acteristics and traits associated with PA levels, which may
modify also the size of the genetic effects on PA in a context-
dependent manner.
The main aim of this study was to calculate PRS for PA using
UK Biobank GWAS summary statistics and then evaluate their
out-of-sample predictive values in the Finnish Twin Cohorts
(FTC) and theNorthern FinlandBirth Cohort 1966 (NFBC1966)
using different PA phenotypes. We hypothesized that the PRS
will account for a statistically significant proportion of the varia-
tion in PA. To deepen our understanding, we also compared the
results between single-nucleotide polymorphism (SNP)–based
and pedigree-based PA heritability analyses. In addition, to eval-
uate the usability of PRS for PA in clinical work, we compared
how much of the variation in objectively measured PA is ex-
plained by simple questionnaire items compared with PRS.
METHODS
Study samples.FTC andNFBC1966 data, in addition to the
open UK Biobank summary level data, were used in this study.
Data on participants from three FTC (Old twin cohort,
Finntwin16, and Finntwin12) (15,16) were included in this
study (N = 11,528 for both genetic and self-reported PA data;
mean age, 44 yr (range, 18–93 yr); 46% male participants).
From a subgroup of the Old twin cohort, 765 individuals had
both genetic and objectively measured PA data (MOBILETWIN
study; mean age, 73 yr (range, 71–75 yr); 46%male participants)
(17). The twin studies were approved by the ethics committees of
the University of Helsinki (113/E3/01 and 346/E0/05), Hel-
sinki University Central Hospital (136/E3/01, 01/2011, 270/
13/03/01/2008, and 154/13/03/00/2011), and Ethics Commit-
tee of the Southwest Finland (MOBILETWIN).
NFBC1966 comprises children born for mothers fromOulu
and Lapland (Finland) and who had their expected date of
birth between January 1 and Dec 31, 1966 (18). Data on cohort
members’ self-reported PA and objectively measured PAwere
collected at the age of 46 yr (19), and genome-wide data were
obtained at the 31-yr follow-up (20). Both genetic data and
self-reported PA data were available for 4061 individuals,
and genetic data plus objectively measured data from
3263–3437 individuals (48% male participants). The Ethics
Committee of the Northern Ostrobothnia Hospital District,
Oulu, Finland, approved the study (94/2011).
Open UK Biobank GWAS summary-level data were used in
the generation of PRS for PA. TheUKBiobank comprises exten-
sive phenotypic data on some 500,000 individuals of the general
UK population age between 40 and 69 yr (21). Self-reported PA
data for this study were available from 321,309 individuals, and
data on objective measurement for PA from 91,105 individuals
(44%male participants). The NorthWest Multi-Centre Research
Ethics Committee approved the UK Biobank study.
In all study samples, the individuals having data on age, sex,
height, weight, genetic data, and data on objectively measured
or self-reported PAwere included in the analyses of this study.
All samples were collected, and studies were conducted in ac-
cordance with the Declaration of Helsinki. Written informed
consent was obtained from all participants.
PA variables. In FTC, the assessment of the leisure-time
MET score was based on a series of structured questions on
leisure-time PA (monthly frequency, mean duration, andmean
intensity of sessions) and PA during commuting (22). The in-
dex was calculated by assigning a MET value to each activity
and by calculating the product of that activity: intensity–
duration–frequency. The MET score was expressed as the
sum score of leisure-time PA MET-hours per day (22). In
the MOBILETWIN study, PA was measured with a hip-
worn triaxial accelerometer (Hookie AM20; Traxmeet Ltd,
Espoo, Finland) for 7 d, and the mean duration of daily
moderate-to-vigorous PA (MVPA) and mean number of daily
steps were calculated; for details, see Waller et al. (17).
In NFBC1966, the leisure-time PA was self-reported with
questions on the frequency and duration of light and brisk
physical activities during leisure time. Brisk PAwas described
as causing at least some sweating and breathlessness, whereas
light PAwas defined as causing no sweating or breathlessness.
PA frequency had six response options: 1) once a month or
less often, 2) two to three times a month, 3) once a week,
4) two to three times a week, 5) four to six times a week,
and 6) daily. PA duration had the following response options:
1) not at all, 2) less than 20 min, 3) 20–39 min, 4) 40–59 min
5) 1–1.5 h, and 6) more than 1.5 h. Daily averages of MET-
hour scores of light and brisk PA were calculated by multiply-
ing the PA volume (duration–frequency) by its intensity (light
PA, 3 METs; brisk PA, 5 METs) (23). PA was objectively
measured with wrist-worn Polar Active monitors (Polar
Electro Oy, Kempele, Finland) for 14 d. Polar Active is a water-
proof accelerometer providingMET values every 30 s based on
daily PA (24). The participants were asked to wear the Polar
Active monitor 24 h·d−1 for at least 14 d on the nondominant
hand. Measured PA with intensity ≥3.5 METs was classified
as MVPA and calculated as daily averages (minutes per day)
(19). In addition, mean number of daily steps was calculated.
When constructing PRS, UK Biobank GWAS results of the
self-report question on the “number of days/week of moderate
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PA 10+ min” (PRSreported) and objectively measured overall
activity measured with Axivity AX3 wrist accelerometer for
7 d (PRSmeasured) (6) were used. A basic linear regression with
sex and the first 10 principal components as covariates was
performed on the GWAS used for the construction of the
PRSreported and linear mixed-model regression on the GWAS
used for PRSmeasured (6). The mean “number of days/week of
moderate PA” was 3.7 (SD, 2.3), and the distribution of the
variable, that is, UK Biobank Data-Field 884, can be seen
from the online showcase of UK Biobank resources (25).
The objectively measured overall activity phenotype is a con-
tinuous phenotype based on 7-d wrist accelerometry and is the
average vector magnitude for each 30-s epoch, and is de-
scribed in more detail by Doherty et al. (26). The SNP-based
genetic correlation (rg) of these UK Biobank PA variables
has been reported to be 0.35 (6).
Genotyping, quality control, and imputation in FTC.
Chip genotyping was done using Illumina Human610-
Quad v1.0 B, Human670-QuadCustom v1.0 A, Illumina
HumanCoreExome (12 v1.0 A, 12 v1.1 A, 24 v1.0 A, 24
v1.1 A, 24 v1.2 A), and Affymetrix FinnGen Axiom arrays.
The algorithms for genotype calling were Illumina’s GenCall
for all HumanCoreExome chip genotypes, Illuminus for 610k
and 670k chip genotypes, and AxiomGT1 for Affymetrix chip
genotypes. Genotype quality control was done in three batches
(batch1: 610k + 670k, batch2: HumanCoreExome, and batch3:
Affymetrix chip genotypes), with removing variants with call
rate less than 97.5% (batch1 and batch3) and 95% (batch2), re-
moving samples with call rate less than 98% (batch1) or 95%
(batch2 and batch3), removing variants with its minor allele
frequency less than 1%, and Hardy–Weinberg equilibrium
P value lower than 1  10−6. Also, samples from all batches
with heterozygosity test method-of-moments F coefficient es-
timate value less than −0.03 or higher than 0.05 (batch1 and
batch2) or ±4 SD from the mean (batch3) were removed along
with the samples that failed sex check or were among the mul-
tidimensional scaling principal component analysis outliers.
Total amounts of genotyped autosomal variants after quality
control were 475,526 (batch1), 239,894 (batch2), and 388,673
(batch3), with following numbers of samples remaining for im-
putation: 2617 (batch1), 5328 (batch2), and 8218 (batch3).
We then performed prephasing using Eagle v2.3 (27) and
imputation with Minimac3 v2.0.1 using the University of
Michigan Imputation Server (28). Genotypes of all batches were
imputed to Haplotype Reference Consortium release 1.1 refer-
ence panel (29).
Genotyping, quality control, and imputation in
NFBC1966. Genotyping was performed using Illumina Hu-
man CNV370-Duo DNA bead chip as described previously
by Sabatti et al. (20). The following quality control steps were
applied: SNP with call rate <95% or minor allele frequency
<0.05 was excluded from the study along with individuals
with genotyping success rate <95%. Imputation to 1000 Ge-
nomes phase 3 reference panel (30) was performed using
prephasing software SHAPEIT v2 (31) and imputation soft-
ware IMPUTE2 v2.3.0 (32).
Polygenic scoring. PRS was constructed for self-reported
(PRSreported) and objectively measured PA (PRSmeasured); see
the “PA variables” section. To obtain PRS, we implemented a
Bayesian approach taking account the linkage disequilibrium
between each variant (LDpred) (33), and therefore, any pruning
or thresholding method to select variants was not used. The in-
finitesimal model for polygenic scoring was adjusted with LD
reference panel, which consists of 27,284 unrelated Finnish
samples from the national FINRISK study (34). GWAS
summary statistics from the UK Biobank for the risk score
calculation were obtained from Neale laboratory repository
of summary statistics (35) (questionnaire-based data) or
from the data-sharing repository of GWAS of PA measured
by accelerometer (6). There were weights from 91,105 to
321,309 samples for the risk score calculation. The LD refer-
ence panel, summary statistics, and the target study samples
of FTC and NFBC1966 were restricted to HapMap3 (36) variants
with European minor allele frequency > 5% and excluding the
major histocompatibility complex region from chromosome 6
(GRCh37: 6p22.1–21.3), representing the whole genome captur-
ing the polygenic signal and which tends to be well imputed for
samples of European or Finnish ancestry. Total number of variants
used for risk score calculation varied from 1,140,182 to 1,142,416
in FTC and from 1,140,159 to 1,142,392 in NFBC1966.
Associations between PRS and self-reported or
measured PA. On the basis of previous knowledge on the
different types of self-reported and objectively monitored PA
variables and their heritability, we focused on analyzing
whether PRSreported predicts self-reported PA and whether
PRSmeasured predicts either self-reported or objectively mea-
sured PA in the Finnish cohorts. The proportion of total varia-
tion of PA outcomes explained by the model (R2) was
estimated by generalized linear regression models. All PRS
values were scaled to obtain standardized normal distribution,
with a mean of zero and an SD of 1. Basic models were ad-
justed for four genetic principal components and sex in FTC
and NFBC1966 and also for age in FTC. We also report the
change in R2 (ΔR2) when PRS was included in the model after
the other predictors. Square root transformation ofMVPAwas
used because of the violation of the assumption of normal dis-
tribution both in FTC and in NFBC1966 and of daily MET
score in NFBC1966. In the linear mixed-model regression of
the FTC data, the within-pair dependency was accounted for
by using the family identifier as the random effect of the
models. Individuals were divided to PRS deciles, and daily
MET score, MVPA, and steps were compared between the first
and last deciles with independent-samples t-test or Mann–
Whitney’s test. The level of significance was set at P < 0.05.
Pedigree and SNP-based heritabilities in FTC. We
estimated pedigree- and SNP-based heritabilities simulta-
neously using the same set of SNP values that were used in
the PRS calculations. We implemented a method (GCTA-
GREML) according to Zaitlen et al. (37) and Yang et al.
(38), where the heritability is calculated using two genetic re-
latedness matrices where the first takes into account only the
heritability caused by family structure and the second takes
http://www.acsm-msse.org1520 Official Journal of the American College of Sports Medicine
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into account only the genetic part of the heritability, so that in
the first matrix, the off-diagonals less than 0.05 were set to 0,
letting the second matrix to have values less than 0.5 indicat-
ing possible distant genetic relationships between samples.
Both of the matrices were used as the fixed effect of the linear
mixed model. Using this method, there were no need to drop
any related samples from the analysis. The difference between
these two heritabilities is called missing (or hidden) heritabil-
ity (37). SNP-based heritabilities for the UKBiobank PAmea-
sures were obtained from association results using LD score
regression (39) restricted to the same set of HapMap3 SNP
values that were used for PRS calculations.
Questionnaire items versus PRSmeasured in
explaining variation in objectively measured PA. In
the MOBILETWIN study (17), complete data from 640 indi-
viduals were available to analyze how much of the variation
in objectively measured PA (MVPA and steps) could be
accounted for by questionnaire-based data (age, sex, body
mass index, self-reported distance walked or jogged outdoors,
self-reported fitness, self-reported mobility-restricting disease,
and self-reported PA category) and by PRSmeasured. This meth-
odology and results are described in more detail in Supplemen-
tal Digital Content 1, questionnaire items versus PRSmeasured in
explaining variation in objectively measured PA, http://links.
lww.com/MSS/B929.
RESULTS
PRS. The PRSreported accounted for 0.24% and 0.25% of
the variation (R2) in the reported daily MET scores in
NFBC1966 and FTC (P values = 0.0017 and <0.0001, respec-
tively; Table 1). The PRSmeasured accounted from 0.07% to
1.44% of the variation in the self-reported and objectively
measured PA (P value range = 0.023 to <0.0001; Table 1).
For all studied PA volume variables, individuals in the highest
PRS deciles compared with the lowest PRS deciles had signif-
icantly (11%–28%) higher PA volume both in FTC and in
NFBC1966 (P values = 0.017 to <0.0001; Table 2). Figure 1
shows the means of the objectively measured PA variables
in MOBILETWIN and NFBC1966 according to PRSmeasured
deciles. The associations are quite similar despite differences
in age and measurement method between the MOBILETWIN
and NFBC1966 studies.
Pedigree and SNP heritabilities in FTC. The pedigree
heritabilities (37%–56%) and heritability explained by SNP in
FTC are shown in Table 3. The results show that the missing
(or hidden) heritability estimates (34%–40%) are higher than
those of SNP heritabilities (7%–19%). The SNP-based heri-
tabilities (SNP-h2 (LD score regression)) obtained from UK
Biobank PA association results were 0.040 (SE, 0.002;
P < 0.0001) for reported “number of days/week of moderate
PA 10+ min” and 0.143 (SE, 0.008; P < 0.0001) for measured
overall PA.
Questionnaire items versus PRSmeasured in explaining
variation inmeasuredPA in theMOBILETWINstudy. For
details of the results, see Supplemental Digital Content 1,
questionnaire items versus PRSmeasured in explaining variation
in objectively measured PA, http://links.lww.com/MSS/B929.
Self-reported weekly walking or running distance outdoors
accounted for the highest amount of variation in objectively
TABLE 1. Associations between PRS and PA variables in FTC and NFBC1966.
Variables β (SE)a Pa R2% (95% CI)b ΔR2%c N
PRS for number of days/week of moderate PA 10+ min in UK Biobank (PRSreported)
Reported daily MET score in FTC 0.1717 (0.0323) <0.0001 5.38 (4.50–6.25) 0.25 11,528
Reported daily MET score in NFBC1966 0.0355 (0.0113) 0.0017 1.07 (0.52–1.62) 0.24 4061
PRS for measured overall activity in UK Biobank (PRSmeasured)
Reported daily MET score in FTC 0.0908 (0.0321) 0.0046 5.20 (4.45–6.04) 0.07 11,528
Reported daily MET score in NFBC1966 0.0405 (0.0112) 0.0003 1.15 (0.58–1.71) 0.32 4061
Measured daily MVPA in MOBILETWIN 2.497 (1.093) 0.0227 3.73 (0.85–6.60) 0.90 759
Measured daily MVPA in NFBC1966 0.1620 (0.0335) <0.0001 8.54 (7.11–9.96) 0.62 3437
Measured daily steps in MOBILETWIN 369.8 (123.3) 0.0028 2.71 (0.14–5.28) 1.44 759
Measured daily steps in NFBC1966 365.82 (64.04) <0.0001 3.71 (2.72–4.69) 0.96 3263
aEffect and P value adjusted for age, sex, and four genetic principal components.
bVariation accounted for by age, sex, and the PRS with family number as random effect of the linear mixed model in FTC.
cΔR2 = difference of R-squared between models with and without PRS included.
CI, confidence interval.
TABLE 2. Physical activity volumes of Finnish individuals in the lowest and highest PRS deciles.
Variables
Lowest PRS Decile Highest PRS Decile
P*Mean (95% CI)
PRS for number of days/week of moderate PA 10+ min in UK Biobank (PRSreported)
Reported daily MET score in FTC, METh 2.76 (2.59–2.93) 3.45 (3.23–3.67) <0.0001
Reported daily MET score in NFBC1966, METh 2.19 (2.0–2.38) 2.68 (2.44–2.91) 0.017
PRS for measured overall activity in UK Biobank (PRSmeasured)
Reported daily MET in FTC, METh 3.12 (2.94–3.30) 3.51 (3.29–3.73) <0.0001
Reported daily MET score in NFBC1966, METh 2.18 (1.99–2.38) 2.69 (2.46–2.93) 0.002
Measured daily MVPA in MOBILETWIN, min 33.7 (28.1–39.3) 43.3 (36.3–50.3) <0.0001
Measured daily MVPA in NFBC1966, min 63.1 (59.8–66.4) 73.9 (69.8–77.9) <0.0001
Measured daily steps in MOBILETWIN, steps 5742 (5062–6422) 6989 (6216–7762) <0.0001
Measured daily steps in NFBC1966, steps 10,070 (9705–10,435) 11,219 (10,803–11,634) <0.0001
*P for difference between the highest and lowest deciles.
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measured MVPA (R2 = 44%) and daily steps (R2 = 36%).
Bodymass index, self-reported fitness level, mobility restricting
disease, and PA category accounted for lower amounts of vari-
ation (R2 = 11%–23%).Multivariable model including age, sex,
body mass index, and the physical fitness and activity related
self-reports accounted for 57% of the variation in MVPA and
47% in daily steps. Adding the PRSmeasured into the models in-
creased the proportion of total variation explained by the
model only by 0.03% for MVPA and 0.31% for daily steps.
DISCUSSION
Our study adds to the understanding on the out-of-sample
predictive value of PRS for PA using different self-report
and objectively measured PA methods. PRS constructed on
the basis of UK Biobank results explained statistically signifi-
cantly PA in the Finnish cohorts, but the variation accounted
for was small compared with some questionnaire-reported pa-
rameters such as physical fitness or health status.
Leisure-time or total PA is influenced by sex, body mass in-
dex, education, occupation, family commitments, physical fit-
ness, occurrence of chronic diseases, environmental factors,
and many other factors, whose influence also varies with age
and with study area (14,40). These variables may mediate or
modify the relationship of genetic liability to PA with the ob-
served phenotype.
In addition to the aforementioned determinants of PA, there
may be other reasons why our observed explanation rates of
PRS constructed based on UK Biobank results to account for
the variation in the Finnish cohorts were low. First, UK
Biobank and the Finnish cohorts used differing methods both
to assess self-reported and to assess objectively measured PA.
Second, there may be genetic differences between the studied
populations as we are predicting from a general European pop-
ulation to a genetic isolate (41). Third, as the SNP heritabilities
were statistically significant but low compared with pedigree
heritabilities, there may be hidden genetic factors not covered
by the variants used in the calculation of PRS. Among the
FIGURE 1—Means and SEMs of the objectively measured daily MVPA minutes (upper panel) and daily steps (lower panel) in the MOBILETWIN and
NFBC1966 studies according to PRSmeasured deciles. PRSmeasured constructed based on the objective measurement of overall activity in UK Biobank.Dotted
line is the trend line, and R2 is from the bivariate decile mean-decile model to illustrate trend linearity between the PA decile means and the PRS deciles.
TABLE 3. Pedigree, SNP, and missing heritabilities in FTC.
Variables Pedigree-h2 SNP-h2
Missing Heritability
(Pedigree – SNP-h2
Difference)
Reported daily met
score in FTC
0.416 (SE, 0.017),
P = 0.0026
0.071 (SE, 0.027),
P = 0.0026
0.345 (0.032)
Measured daily MVPA
in MOBILETWIN
0.564 (SE, 0.061),
P = 0.326
0.191 (SE, 0.413),
P = 0.326
0.374 (0.417)
Measured daily steps
in MOBILETWIN
0.481 (SE, 0.062),
P = 0.432
0.0776 (SE, 0.418),
P = 0.432
0.403 (0.423)
h2, heritability.
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proposed explanations for this missing (hidden) heritability
is the existence of many unidentified common variants with
very small effect sizes, rare variants not captured by current
genotyping platforms, structural variants, epistatic interac-
tions, gene–environment interactions, or parent-of-origin
effects (37,42,43). Interestingly, new research (43) showed
that pedigree heritability for height and body mass index
seemed to be fully recovered from whole-genome sequence
data in the analysis including also rare variants. These hidden
genetic factors may also contribute to the differences between
the pedigree and SNP heritabilities for PA in our study, as well
as the low explanation rates of the constructed PRS to explain
variation in PA. SNP heritabilities obtained from UKBiobank
association results using only the effect sizes were statistically
significant but low compared with pedigree heritabilities ob-
tained from the FTC subjects using the whole genome and
phenotypic information together. The SNP heritabilities in
FTC were at a similar or slightly higher level compared with
those calculated for the UK Biobank PA variables using the
same set of SNP (5).
Expectedly, there were simple questions that accounted for
more of the variation in measured PA in the MOBILETWIN
individuals than PA PRS calculated based on the findings
from another cohort. The questionnaire items also contribute
to the understanding why PRS accounts for only a small pro-
portion of the variation of the PA measures.
PAmeasurements differed between the studied populations,
which can be considered either as a limitation or as a strength
in our study. From UK Biobank results, we selected clinically
relevant self-report and objectively monitored PA variables
based on which calculation of PA PRS was possible. Then
we used clinically relevant variables (self-reported PA volume
andmeasured dailyMVPAminutes and steps) from the Finnish
cohorts to study the associations of PRS and PA. Although all
these indicators of PA describe PA volumes, they are not iden-
tical. We did not have access to the original UK Biobank data
to construct new PA variables. However, to evaluate the addi-
tional value of combining information from the different self-
reports, we performed a joint analysis of the UK Biobank
GWAS results for reported moderate and reported vigorous
activity using multitrait analysis of GWAS (MTAG). However,
this new PRSreported MTAG predicted reported daily MET score
in FTC only slightly better than the PRSreported with ΔR
2 values
of 0.32% versus 0.25% (for details, see Supplemental Digital
Content 2, polygenic scoring on MTAG-estimated effects,
http://links.lww.com/MSS/B930). The PRS constructed on the
basis of UK Biobank self-reported PA questions did not predict
statistically significantly objective measured PA variables in
FTC (results not shown). The used objective PA measurements
do not differentiate between leisure-time and work-related or
household activities and thus indicate total PA volume in a dif-
ferent way than self-reports. Differing genetic factors may pre-
dict work-related and leisure-time PA. An additional difference
between self-reported and objectively measured PA volumes is
that self-reports take the subjective intensity into account,
whereas accelerometer data usually are transformed to PA with-
out considering the individual fitness level (44). Individuals with
chronic diseases, low fitness, or advanced biological aging pro-
cess usually move less and more slowly than healthy and high-
fit individuals, although their PA intensity relative to their fitness
level may be the same (44), which again may cause challenges in
the analysis of genetic factors predicting PA. Despite the afore-
mentioned factors, PRS constructed based on UK Biobank data
predicted PA in the Finnish cohorts, which is good news for sci-
entists who are applying Mendelian randomization methods and
do not have the exactly same PA phenotypes in their cohorts as
the UK Biobank study has.
In conclusion, PRS constructed based on UK Biobank re-
sults accounted for statistically significant but overall small
proportion of the variation in PA in the Finnish cohorts.
However, there were significant differences in the PA levels
between the individuals who were in the highest PRS deciles
and those in the lowest PRS deciles. In future studies, using
identical questions or objective measurement methods to as-
sess detailed PA behaviors and possibly including rare var-
iants in the construction of PRS may increase the proportion
of PA explained by the PRS, which may increase the usabil-
ity of PRS for identifying individuals at risk for physical
inactivity.
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